Celgene Corp (CELG)-製薬・医療分野:企業M&A・提携分析

【英語タイトル】Celgene Corp (CELG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA8012250)・商品コード:DATA8012250
・発行会社(調査会社):GlobalData
・発行日:2017年12月14日
・ページ数:299
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp (CELG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
Celgene Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15
Celgene Corp, Medical Devices Deals, 2011 to YTD 2017 17
Celgene Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Celgene Corp, Pharmaceuticals & Healthcare, Deal Details 29
Asset Purchase 29
Celgene Enters into Option Agreement to Acquire Assets of TRPH-222 from Triphase Accelerator 29
Celgene Acquires Marizomib from Triphase Accelerator 30
Celgene Enters into Option to Acquire VEGFR-2/TIE 2 Bi-Specific Antibody from Triphase 31
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 32
Venture Financing 34
Arcus Biosciences Raises USD107 Million in Series C Financing 34
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 36
Evelo Biosciences Raises USD50 Million in Series B Financing 38
Repare Therapeutics Raises USD68 million in Series A Financing 39
Dragonfly Therapeutics Raises Funds through Venture Financing 40
Aadi Bioscience Raises USD23 Million in Series A Venture Financing 41
Grail Raises USD914 Million in First Tranche of Series B Financing 42
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 44
Oncorus Raises Additional USD4 Million in Series A Financing 46
Delinia Raises USD35 Million in Series A Financing 47
Cleave Biosciences Raises USD37 Million in Series B Financing Round 48
Oncorus Raises USD57 Million in Series A Financing Round 50
Sapience Therapeutics Raises USD22.5 Million in Series A Financing 51
Agenovir Raises USD10.6 Million in Series A Venture Financing 52
Ideaya Biosciences Raises USD46 Million in Series A Financing 53
FLX Bio Raises USD50 Million in Series B Financing 55
Armo Biosciences Raises USD50 Million in Series C Financing 57
Zymeworks Raises USD61.5 Million in Series A Financing 59
Cyteir Therapeutics Raises USD5.5 Million in Series A Financing 61
Arcus Biosciences Raises USD50 Million in Series A Financing 62
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 63
CRISPR Therapeutics Raises USD29 Million in Series B Financing 65
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 67
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 69
VentiRx Pharma Raises USD15 Million in Venture Financing 70
VentiRx Pharmaceuticals Secures USD50.6 Million in Venture Funding 71
Atara Biotherapeutics Raises US$52 Million In Series B Financing 72
Sutro Biopharma Raises US$26 Million In Series D Financing 74
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 76
Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 77
PTC Therapeutics Raises US$60 Million In Venture Financing 78
PharmAkea Raises Funds Through Seed Financing 80
Ptc Therapeutics Raises US$30 Million In Venture Financing 81
Acetylon Pharma Raises US$15 Million From Celgene 82
Agios Pharma Secures US$78 Million In Series C Financing 83
Acetylon Pharma Raises Additional US$15.2 Million In Series B Financing 85
Private Equity 86
Celgene to Reject Mini Tender Offer by TRC Capital 86
Partnerships 87
Nimbus Therapeutics Enters into Agreement with Celgene 87
Celgene and BeiGene Enters into Partnership 88
Celgene Enters into Agreement with Forma Therapeutics 89
Dragonfly Therapeutics Enters into Agreement with Celgene 90
IMIDomics Enters into Agreement with Celgene 91
Forma Therapeutics Partners with Celgene 92
Celgene Enters into Research Agreement with Anokion 93
Evotec Enters into Research Agreement with Celgene 94
Celgene Enters into Agreement with IBM Watson Health 95
Celgene Exercises its Option Agreement with Abide Therapeutics 96
Celgene Enters into Agreement with Jounce Therapeutics 97
Celgene Enters into Co-Development Agreement with Sidney Kimmel Comprehensive Cancer Center 98
Celgene Enters into Co-Development Agreement with Tisch Cancer Institute 99
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 100
Celgene Enters into Co-Development Agreement with Herbert Irving Comprehensive Cancer Center 101
TriNetX Partners with Celgene 102
Flatiron Health Partners with Celgene 103
Hereditary Neuropathy Foundation Partners with Acetylon Pharma 104
Inception IBD Enters into Agreement with Celgene 105
Nurix Enters into Co-Development Agreement with Celgene 106
Celgene Partners with Recombinant Antibody Network 107
Celgene Exercises Option Agreement with Juno Therapeutics 108
Lycera Enters into Co-Development Agreement with Celgene 109
Cypher Genomics Enters into Co-Development Agreement with Celgene 110
Adimab Enters into Discovery Agreement with Celgene 111
Celgene Enters into Agreement with Agios Pharma 112
Celgene Enters into Co-Development Agreement with MedImmune 113
Northern Biologics to Enter into R&D Agreement with Celgene 114
Celgene Extends Co-Development Agreement with Agios Pharma Until April 2016 115
Sutro Biopharma Amends Co-Development Agreement with Celgene 117
Bristol-Myers Squibb Enters into Agreement with Celgene 119
NanoString Enters into Co-Development Agreement with Celgene 120
Forma Therapeutics Enters Into Agreement With Celgene 121
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 123
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 124
PharmAkea Therapeutics Extends Agreement with Celgene 126
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 127
Concert Pharma Enters Into Co-Development Agreement With Celgene 128
Presage Biosciences Enters Into Research Agreement With Celgene 130
Triphase Accelerator Enters Into Co-Development Agreement With Celgene 131
Triphase Expands Co-Development Agreement with Celgene 132
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 133
Celgene And PharmAria Enters Into Agreement To Discover Small-Molecule Therapeutic Targets 134
VentiRx Pharma Enters Into Agreement With Celgene To Develop TLR8 Agonist VTX-2337 135
Advinus Therapeutics Enters Into R&D Agreement With Celgene Global Health For Visceral Leishmaniasis 136
Celgene Enters into Co-Development Agreement with AnaptysBio 137
Celgene And Versant Venture Enter Into Co-Development Agreement With Quanticel Pharma 138
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 139
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 140
Celgene Enters Into Co-Development Agreement With Chan Soon-Shiong Institute for Advanced Health For Oncology Therapeutics 141
Licensing Agreements 142
Acceleron Pharma Enters into Licensing Agreement with Celgene 142
BeiGene Enters into Licensing Agreement with Celgene 144
Antengene Enters into Licensing Agreement with Celgene 145
Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 146
Celgene Enters into Licensing Agreement with GNS Healthcare 147
Celgene Exercises Option for Licensing Agreement with GlobeImmune 148
Open Monoclonal Enters into Licensing Agreement with Celgene 149
Celgene Enters into Licensing Agreement with Zymeworks for Bi-Specific Antibody 150
Celgene Exercises Option for Licensing Agreement with Agios Pharma for AG-221 151
Inhibrx Enters into Licensing Agreement with Celgene 152
Epizyme Extends Licensing Agreement with Celgene for HMT Inhibitor Programs 153
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 155
Celgene Enters into Licensing Agreement with Bluebird bio 156
Celgene Exercises Option for Licensing Agreement with Lycera 157
Celgene Enters into Licensing Agreement with Juno Therapeutics 158
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 159
AADi Enters into Licensing Agreement with Celgene for ABI-009 160
Celgene Enters into Licensing Agreement with Nogra Pharma for GED 0301 161
Agios Pharma Exercises Option For Licensing Agreement With Celgene 163
NantBioScience To Enter Into Licensing Agreement With Celgene To Develop Cancer Therapies 165
Celgene Enters into Licensing Agreement with Baylor College of Medicine 167
ProMetic Enters Into An Agreement With Celgene 168
Equity Offering 169
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 169
NantKwest Raises USD17 Million in Private Placement of Shares 170
Mesoblast Raises USD44.8 Million in Private Placement of Shares 171
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 172
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 174
Debt Offering 175
Celgene Prices USD750 Million in Public Offering of 2.750% Notes Due 2023 175
Celgene Prices USD1,000 Million in Public Offering of 3.450% Notes Due 2027 176
Celgene Prices USD1,250 Million in Public Offering of 4.350% Notes Due 2047 177
Celgene Raises USD500 Million in Public Offering of 2.25% Notes Due 2021 178
Celgene Prices Public Offering of 3.55% Notes Due 2022 for USD1 Billion 179
Celgene Prices Public Offering of 5% Notes Due 2045 for USD2 Billion 181
Celgene Prices Public Offering of 2.125% Notes Due 2018 for USD1 Billion 183
Celgene Prices Public Offering of 2.875% Notes Due 2020 for USD1.5 Billion 185
Celgene Prices Public Offering of 3.875% Notes Due 2025 for USD2.5 Billion 187
Celgene Completes Public Offering Of Notes Due 2044 For USD1 Billion 189
Celgene Completes Public Offering Of Notes Due 2019 For USD500 Million 191
Celgene Completes Public Offering Of Notes Due 2024 For USD1 Billion 193
Celgene Completes Public Offering Of Notes Due 2018 For US$400 Million 195
Celgene Completes Public Offering Of Notes Due 2043 For US$400 Million 196
Celgene Completes Public Offering Of Notes Due 2023 For US$700 Million 197
Tengion Completes Private Placement Of Notes Due 2015 For US$15 Million 198
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2022 For US$1 Billion 200
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 201
Acquisition 202
Celgene to Acquire 5.9% Stake in BeiGene for USD150 Million 202
Celgene Acquires VentiRx Pharma 204
Celgene to Acquire Delinia 205
Celgene Acquires Acetylon Pharma 206
Celgene Acquires EngMab for USD600 Million 207
Celgene Acquires Receptos for USD7.2 Billion 208
Celgene to Acquire Quanticel Pharma for USD485 Million 210
Celgene To Acquire Stake In PharmAkea Therapeutics 211
Celgene Invests US$15 Million In Tengion 212
Celgene Completes Acquisition Of Avila Therapeutics, Biotech Company 213
Celgene Corp – Key Competitors 215
Celgene Corp – Key Employees 216
Celgene Corp – Locations And Subsidiaries 217
Head Office 217
Other Locations & Subsidiaries 217
Recent Developments 222
Financial Announcements 222
Oct 26, 2017: Celgene Reports Third Quarter 2017 Operating and Financial Results 222
Jul 27, 2017: Celgene Reports Second Quarter 2017 Operating and Financial Results 224
Apr 27, 2017: Celgene Reports First Quarter 2017 Operating and Financial Results 227
Jan 26, 2017: Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results 229
Jan 09, 2017: Celgene Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance 232
Oct 27, 2016: Celgene Reports Third Quarter 2016 Operating and Financial Results 234
Jul 28, 2016: Celgene Reports Second Quarter 2016 Operating and Financial Results 237
Apr 28, 2016: Celgene Reports First Quarter 2016 Operating and Financial Results 240
Jan 28, 2016: Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results 243
Jan 11, 2016: Celgene Announces 2016 Financial Outlook and Preliminary 2015 Results 247
Jan 11, 2016: Celgene Corporation Announces 2016 Financial Outlook and Preliminary 2015 Results 249
Corporate Communications 251
Feb 23, 2017: Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer 251
Feb 11, 2016: Celgene Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors 252
Jan 11, 2016: Organizational Changes Strengthen Leadership Team and Position Celgene for Long-Term Growth 253
Legal and Regulatory 254
Aug 03, 2017: Multimillion Settlement with Biopharmaceutical Company 254
Product News 255
12/05/2016: Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA) 255
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 256
08/01/2017: FDA Grants Approval Of IDHIFA, The First Oral Targeted Therapy For Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia And An IDH2 Mutation 258
07/12/2016: Mayo Clinic researchers identify potential immunotherapy drug combination 260
06/24/2017: New Data from Phase 1/2 Trial of Oral IDHIFA (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML 261
06/06/2017: Precision therapy enasidenib effective in treating deadly form of leukemia 263
03/07/2016: Oral OTEZLA (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress 264
03/04/2016: Oral OTEZLA (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE Trials to Be Presented at American Academy of Dermatology Congress 266
03/01/2017: FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation 268
Product Approvals 269
Apr 08, 2016: National Institute For Health And Care Excellence (NICE) Issues Draft Decision Not Recommending Vidaza (Azacitidine) As An Option To Treat Acute Myeloid Leukaemia (AML) 269
Clinical Trials 270
Jun 06, 2017: Updated Data from Phase 1 Trial of Oral IDHIFA (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation 270
May 17, 2017: Agios to Present New Clinical Data from Phase 1 Study of Enasidenib at ASCO 272
Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma 273
Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting 275
Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting 276
Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting 278
Nov 30, 2016: bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma 279
Nov 18, 2016: Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 280
Nov 14, 2016: bluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium 281
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 282
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 283
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 284
Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 285
Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 286
Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 288
Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 290
Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 291
Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS 293
Feb 17, 2016: bluebird bio Announces First Patient Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 295
Other Significant Developments 296
Dec 05, 2017: Celgene Launches Celgene Cancer Care Links to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries 296
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 297
Jan 12, 2016: Forma Therapeutics Achieves An Additional Major Objective In Collaboration With Celgene To Advance Innovative Protein Homeostasis Drugs 298
Appendix 299
Methodology 299
About GlobalData 299
Contact Us 299
Disclaimer 299

List of Tables
Celgene Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
Celgene Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
Celgene Corp, Deals By Therapy Area, 2011 to YTD 2017 15
Celgene Corp, Medical Devices Deals, 2011 to YTD 2017 17
Celgene Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Celgene Enters into Option Agreement to Acquire Assets of TRPH-222 from Triphase Accelerator 29
Celgene Acquires Marizomib from Triphase Accelerator 30
Celgene Enters into Option to Acquire VEGFR-2/TIE 2 Bi-Specific Antibody from Triphase 31
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 32
Arcus Biosciences Raises USD107 Million in Series C Financing 34
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 36
Evelo Biosciences Raises USD50 Million in Series B Financing 38
Repare Therapeutics Raises USD68 million in Series A Financing 39
Dragonfly Therapeutics Raises Funds through Venture Financing 40
Aadi Bioscience Raises USD23 Million in Series A Venture Financing 41
Grail Raises USD914 Million in First Tranche of Series B Financing 42
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 44
Oncorus Raises Additional USD4 Million in Series A Financing 46
Delinia Raises USD35 Million in Series A Financing 47
Cleave Biosciences Raises USD37 Million in Series B Financing Round 48
Oncorus Raises USD57 Million in Series A Financing Round 50
Sapience Therapeutics Raises USD22.5 Million in Series A Financing 51
Agenovir Raises USD10.6 Million in Series A Venture Financing 52
Ideaya Biosciences Raises USD46 Million in Series A Financing 53
FLX Bio Raises USD50 Million in Series B Financing 55
Armo Biosciences Raises USD50 Million in Series C Financing 57
Zymeworks Raises USD61.5 Million in Series A Financing 59
Cyteir Therapeutics Raises USD5.5 Million in Series A Financing 61
Arcus Biosciences Raises USD50 Million in Series A Financing 62
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 63
CRISPR Therapeutics Raises USD29 Million in Series B Financing 65
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 67
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 69
VentiRx Pharma Raises USD15 Million in Venture Financing 70
VentiRx Pharmaceuticals Secures USD50.6 Million in Venture Funding 71
Atara Biotherapeutics Raises US$52 Million In Series B Financing 72
Sutro Biopharma Raises US$26 Million In Series D Financing 74
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 76
Acetylon Pharmaceuticals Secures USD100 Million in Fundnig from Celgene 77
PTC Therapeutics Raises US$60 Million In Venture Financing 78
PharmAkea Raises Funds Through Seed Financing 80
Ptc Therapeutics Raises US$30 Million In Venture Financing 81
Acetylon Pharma Raises US$15 Million From Celgene 82
Agios Pharma Secures US$78 Million In Series C Financing 83
Acetylon Pharma Raises Additional US$15.2 Million In Series B Financing 85
Celgene to Reject Mini Tender Offer by TRC Capital 86
Nimbus Therapeutics Enters into Agreement with Celgene 87
Celgene and BeiGene Enters into Partnership 88
Celgene Enters into Agreement with Forma Therapeutics 89
Dragonfly Therapeutics Enters into Agreement with Celgene 90
IMIDomics Enters into Agreement with Celgene 91
Forma Therapeutics Partners with Celgene 92
Celgene Enters into Research Agreement with Anokion 93
Evotec Enters into Research Agreement with Celgene 94
Celgene Enters into Agreement with IBM Watson Health 95
Celgene Exercises its Option Agreement with Abide Therapeutics 96
Celgene Enters into Agreement with Jounce Therapeutics 97
Celgene Enters into Co-Development Agreement with Sidney Kimmel Comprehensive Cancer Center 98
Celgene Enters into Co-Development Agreement with Tisch Cancer Institute 99
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 100
Celgene Enters into Co-Development Agreement with Herbert Irving Comprehensive Cancer Center 101
TriNetX Partners with Celgene 102
Flatiron Health Partners with Celgene 103
Hereditary Neuropathy Foundation Partners with Acetylon Pharma 104
Inception IBD Enters into Agreement with Celgene 105
Nurix Enters into Co-Development Agreement with Celgene 106
Celgene Partners with Recombinant Antibody Network 107
Celgene Exercises Option Agreement with Juno Therapeutics 108
Lycera Enters into Co-Development Agreement with Celgene 109
Cypher Genomics Enters into Co-Development Agreement with Celgene 110
Adimab Enters into Discovery Agreement with Celgene 111
Celgene Enters into Agreement with Agios Pharma 112
Celgene Enters into Co-Development Agreement with MedImmune 113
Northern Biologics to Enter into R&D Agreement with Celgene 114
Celgene Extends Co-Development Agreement with Agios Pharma Until April 2016 115
Sutro Biopharma Amends Co-Development Agreement with Celgene 117
Bristol-Myers Squibb Enters into Agreement with Celgene 119
NanoString Enters into Co-Development Agreement with Celgene 120
Forma Therapeutics Enters Into Agreement With Celgene 121
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 123
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 124
PharmAkea Therapeutics Extends Agreement with Celgene 126
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 127
Concert Pharma Enters Into Co-Development Agreement With Celgene 128
Presage Biosciences Enters Into Research Agreement With Celgene 130
Triphase Accelerator Enters Into Co-Development Agreement With Celgene 131
Triphase Expands Co-Development Agreement with Celgene 132
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 133
Celgene And PharmAria Enters Into Agreement To Discover Small-Molecule Therapeutic Targets 134
VentiRx Pharma Enters Into Agreement With Celgene To Develop TLR8 Agonist VTX-2337 135
Advinus Therapeutics Enters Into R&D Agreement With Celgene Global Health For Visceral Leishmaniasis 136
Celgene Enters into Co-Development Agreement with AnaptysBio 137
Celgene And Versant Venture Enter Into Co-Development Agreement With Quanticel Pharma 138
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 139
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 140
Celgene Enters Into Co-Development Agreement With Chan Soon-Shiong Institute for Advanced Health For Oncology Therapeutics 141
Acceleron Pharma Enters into Licensing Agreement with Celgene 142
BeiGene Enters into Licensing Agreement with Celgene 144
Antengene Enters into Licensing Agreement with Celgene 145
Regenacy Pharma Receives Rights to HDAC6 Inhibitor, Ricolinostat ACY-1215 from Acetylon Pharma 146
Celgene Enters into Licensing Agreement with GNS Healthcare 147
Celgene Exercises Option for Licensing Agreement with GlobeImmune 148
Open Monoclonal Enters into Licensing Agreement with Celgene 149
Celgene Enters into Licensing Agreement with Zymeworks for Bi-Specific Antibody 150
Celgene Exercises Option for Licensing Agreement with Agios Pharma for AG-221 151
Inhibrx Enters into Licensing Agreement with Celgene 152
Epizyme Extends Licensing Agreement with Celgene for HMT Inhibitor Programs 153
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 155
Celgene Enters into Licensing Agreement with Bluebird bio 156
Celgene Exercises Option for Licensing Agreement with Lycera 157
Celgene Enters into Licensing Agreement with Juno Therapeutics 158
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 159
AADi Enters into Licensing Agreement with Celgene for ABI-009 160
Celgene Enters into Licensing Agreement with Nogra Pharma for GED 0301 161
Agios Pharma Exercises Option For Licensing Agreement With Celgene 163
NantBioScience To Enter Into Licensing Agreement With Celgene To Develop Cancer Therapies 165
Celgene Enters into Licensing Agreement with Baylor College of Medicine 167
ProMetic Enters Into An Agreement With Celgene 168
Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 169
NantKwest Raises USD17 Million in Private Placement of Shares 170
Mesoblast Raises USD44.8 Million in Private Placement of Shares 171
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 172
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 174
Celgene Prices USD750 Million in Public Offering of 2.750% Notes Due 2023 175
Celgene Prices USD1,000 Million in Public Offering of 3.450% Notes Due 2027 176
Celgene Prices USD1,250 Million in Public Offering of 4.350% Notes Due 2047 177
Celgene Raises USD500 Million in Public Offering of 2.25% Notes Due 2021 178
Celgene Prices Public Offering of 3.55% Notes Due 2022 for USD1 Billion 179
Celgene Prices Public Offering of 5% Notes Due 2045 for USD2 Billion 181
Celgene Prices Public Offering of 2.125% Notes Due 2018 for USD1 Billion 183
Celgene Prices Public Offering of 2.875% Notes Due 2020 for USD1.5 Billion 185
Celgene Prices Public Offering of 3.875% Notes Due 2025 for USD2.5 Billion 187
Celgene Completes Public Offering Of Notes Due 2044 For USD1 Billion 189
Celgene Completes Public Offering Of Notes Due 2019 For USD500 Million 191
Celgene Completes Public Offering Of Notes Due 2024 For USD1 Billion 193
Celgene Completes Public Offering Of Notes Due 2018 For US$400 Million 195
Celgene Completes Public Offering Of Notes Due 2043 For US$400 Million 196
Celgene Completes Public Offering Of Notes Due 2023 For US$700 Million 197
Tengion Completes Private Placement Of Notes Due 2015 For US$15 Million 198
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2022 For US$1 Billion 200
Celgene Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 201
Celgene to Acquire 5.9% Stake in BeiGene for USD150 Million 202
Celgene Acquires VentiRx Pharma 204
Celgene to Acquire Delinia 205
Celgene Acquires Acetylon Pharma 206
Celgene Acquires EngMab for USD600 Million 207
Celgene Acquires Receptos for USD7.2 Billion 208
Celgene to Acquire Quanticel Pharma for USD485 Million 210
Celgene To Acquire Stake In PharmAkea Therapeutics 211
Celgene Invests US$15 Million In Tengion 212
Celgene Completes Acquisition Of Avila Therapeutics, Biotech Company 213
Celgene Corp, Key Competitors 215
Celgene Corp, Key Employees 216
Celgene Corp, Other Locations 217
Celgene Corp, Subsidiaries 217

★調査レポート[Celgene Corp (CELG)-製薬・医療分野:企業M&A・提携分析] (コード:DATA8012250)販売に関する免責事項を必ずご確認ください。
★調査レポート[Celgene Corp (CELG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆